Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

doi:10.1093/jnci/dji238

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Journal of the National Cancer Institute - 17 Aug 2005

Mukohara Toru, Engelman Jeffrey A, Hanna Nasser H, Yeap Beow Y, Kobayashi Susumu, Lindeman Neal, Halmos Balázs, Pearlberg Joseph, Tsuchihashi Zenta, Cantley Lewis C, Tenen Daniel G, Johnson Bruce E, Jänne Pasi A

Abstract excerpt

BACKGROUND: Many patients with non-small-cell lung cancer (NSCLC) who achieve radiographic responses to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib have somatic mutations in the EGFR tyrosine kinase domain. However, little is known...

Topics

Adenocarcinoma
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Apoptosis
Blotting, Western
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cetuximab
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Gefitinib

Humans

Lung Neoplasms

Mutation

Phosphorylation

Protein Kinase Inhibitors

Quinazolines

Source

Open in PubMed

Identifiers

PMID: 16106023
DOI: 10.1093/jnci/dji238

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-16106023-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.PMID 16106023Read ↗

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.Semantic proximity Read ↗

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.Semantic proximity Read ↗

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.Semantic proximity Read ↗

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.Semantic proximity Read ↗

EGFR-directed monoclonal antibodies in non-small cell lung cancer.Semantic proximity Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.Semantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.